Addressing Myelotoxicity as a Consequence of Treatment for Extensive-Stage Small Cell Lung Cancer

This digital series raises awareness regarding the challenges in treating extensive-stage small cell lung cancer through a review of the current treatment landscape, recently approved therapeutics, and emerging options for addressing the consequences of treatment.

EP. 1: Extensive-Stage Small Cell Lung Cancer Treatment Landscape

September 20th 2021

This article explores the treatment options for extensive-stage small cell lung cancer, including recent approvals of combination regimens, and considers treatment consequences that can lead to further complications.

EP. 2A: Treatment Challenges and Unmet Needs in Extensive-Stage Small Cell Lung Cancer

October 18th 2021

Dr. Jared Weiss of the University of North Carolina Lineberger Comprehensive Cancer Center considers treatment challenges and unmet needs in the current standard-of-care management of extensive-stage small cell lung cancer.

EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung Cancer

October 25th 2021

In this companion article, Dr. Jared Weiss provides key insights into recent advancements in the standard of care for extensive-stage small cell lung cancer and examines challenges affecting treatment.

EP. 3: Management of Extensive-Stage Small Cell Lung Cancer Treatment-Related Events

November 22nd 2021

This article reviews the impact of chemotherapy-induced myelosuppression associated with current standard-of-care management of extensive-stage small cell lung cancer and examines new and emerging therapies that may have the potential to address unmet needs.

EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC

December 22nd 2021

In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.

EP. 4B: Considering Chemotherapy-Induced Myelosuppression and the Impact of Trilaciclib on Its Management

January 28th 2022

In this companion article, Dr. Lowell L. Hart shares key insights into how trilaciclib has begun to impact the management of chemotherapy-induced myelosuppression in patients with SCLC.

EP. 5: Clinical Trial Evidence for the Myeloprotective Benefit of Trilaciclib for Chemotherapy-Induced Myelosuppression

March 25th 2022

This article presents key findings on the safety and efficacy of trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

EP. 6A: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice

April 26th 2022

In the third video of the series, Dr. Jyoti Malhotra from the Rutgers Cancer Institute of New Jersey shares expert insights on the benefits of using trilaciclib in clinical practice including considerations for chemotherapy treatment efficacy and patient quality of life. As of May 1, 2022, Dr. Malhotra is no longer with Rutgers Cancer Institute; she is now affiliated with City of Hope.

EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer

May 11th 2022

In this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

EP. 7: Clinical Trial Evidence for Chemoprotectant Benefit of ALRN-6924 for Chemotherapy-Induced Myelosuppression

May 31st 2022

This article provides an overview of the role of MDM2 and MDMX as drivers of malignancy and examines the potential chemoprotectant benefit of the dual MDM2/MDMX inhibitor ALRN-6924 observed in 2 phase 1b clinical trials of patients with small cell lung cancer and non-small cell lung cancer.